Hepatitis C-related cryoglobulinemic neuropathy: potential role of oxcarbazepine for pain control

Rita Moretti¹, Paola Caruso¹, Matteo Dal Benⁱ,², Silvia Gazzin²* and Claudio Tiribelli²

Abstract

Background: Peripheral neuropathy is one most common, limiting and invalidating neurological symptom in subjects with hepatitis C virus and mixed cryoglobulinemia. Notably, the medical therapy proposed to eradicate HCV, can frequently exacerbate the painful neuropathy. Therefore, neuropathy therapies are insufficient and inadequate, and comprise immunosuppressive drugs, such as steroid or cyclosporine, intravenous immunoglobulin or plasma exchange. These have shown variable success in case reports, with a presumably temporary effect, but with major side effects.

Methods: We assessed the effects of oxcarbazepine treatment in 67 cases of cryoglobulinemia related neuropathy, who did not respond to either steroid or Gabapentin, or Pregabalin. Oxcarbazepine was chosen based on the promising preliminary results.

Results: Patients treated with Oxcarbazepine showed a rapid, discrete and persistent relief of polyneuropathic signs, without consistent side effects, and with a limited interaction with concomitant drugs.

Conclusions: These data favor the use of oxcarbazepine as a useful tool in the management of neuropathic pain associated with Hepatitis–C cryoglobulin neuropathy.

Keywords: HCV, Oxcarbazepine, Neuropathy, Pain

Background

Cryoglobulins are cold-precipitating immunoglobulins [1], which form aggregates and immune complexes, outstripping the reticuloendothelial-clearing activity, depositing in the human tissues, activating the complement, and finally leading to tissue damage, promoting systemic inflammation (usually occurring at the level of skin or kidneys). Otherwise healthy individuals could present cryoglobulins, making difficult to estimate their real prevalence in medical sets, finally considered rare. Nevertheless, the variable clinical manifestations reported in literature, might leads to underestimation of cryoglobulinemia diffusion.

Cryoglobulins can be divided into three types, following the Brouet classification [2], essential, or secondary to autoimmune pathologies and chronic medical conditions (primarily chronic infections) and related to lymphoproliferative diseases [2]. The second and third types, also defined as mixed cryoglobulins [2, 3], composed by monoclonal Ig rheumatoid factor and polyclonal IgG and IgM rheumatoid factor, are seen very frequently in HCV infections [3–7].

Despite varying from country to country, the prevalence of peripheral neuropathies in HCV-associated cryoglobulinemia substantially varies in the Mediterranean [1, 3, 8]. Of note, HCV-related proteins are present in damaged skin, blood vessels, and kidneys and seem to play a direct role in the pathogenesis of the damages seen in the peripheral nerve [1, 9, 10].

Pathological findings suggest a direct damage of the small vessels around nerve, the so-called vasa nervorum [3, 11, 12], due to a vasculitis or to necrotizing arteritis. Both these conditions cause an ischemic damage of nerve [3, 10, 13, 14]. HCV is directly responsive for inducing the
inflammation cascade of events in the vessels, since it has been demonstrated HCV-RNA in epineurial cells [15–17].

Peripheral neuropathy is the most common reported symptom in patients with HCV-associated mixed cryoglobulinemia [18–20], where it may be the first clinical manifestation, despite its prevalence is still unknown. There is only a report [14] assessing the prevalence of peripheral neuropathy in HCV; neuropathy was found in 33% of patients without other cryoglobulinemia-related symptoms and clinically, most frequently, patients present a symmetrical sensory or motor-sensory polyneuropathy, or less frequently as a mono-neuropathy, or as a multiple mononeuropathy [3, 15].

At biopsy, axonal degeneration is shown, possibly triggered by the deposit of cryoglobulins at the level of vasa nervosum microcirculation and vasculitis-induced ischemia, as well, despite seldom reported, by an immunological mediated demyelination. Electrophysiological studies and teased nerve fiber studies allowed neuropathies to be classified as predominantly sensory axonopathy [21, 22], even if there are some descriptions of demyelinating peripheral neuropathies [3, 21–24].

There is no conventional treatment for HCV cryoglobulin neuropathy. It is accepted nowadays that prolonged antiviral therapy led to a reduction of HCV-RNA levels, associated with a reduction of cryoglobulinemia [25]. The reduction of cryoglobulins under the detectable levels has been obtained by treating patients with interferon-alpha (IFN alpha) plus ribavirin, obtaining an amelioration of painful polyneuropathy. On the other hand, the side effects of IFN alpha therapy are known, with the exacerbation of the symptoms of mixed cryoglobulinemia, with an exacerbation of the neuropathy, with severe myalgia, arthralgia [26, 27]. Moreover, there are different cases of described side effects of IFN alpha, such as demyelinating sensory neuropathy, neuropsychiatric symptoms, a possible bone marrow dyscrasia, a transient or definite worsening of hepatitis [22, 28, 29].

For cryoglobulin-related neuropathy, other options have been proposed, including alternative immunosuppressive agents, such as steroid or cyclosporine [30], and plasma exchange [31]. They showed variable success and the effect is presumably temporary. There are some works which stressed the importance of steroids and cyclophosphamide [12]. Considering that peripheral cryoglobulin-related neuropathy in HCV patients give, as the most frequent symptom, the neuropathic pain, the principle target should be its earliest relief and without (or with the most limited) side effects.

After the promising results of a previous work [11], we present a series of many patients, with HCV cryoglobulinemia related polineuropathy, who did not respond to steroid and Gabapentin treatment, but have been successfully managed with Oxcarbazepine.

### Methods

#### Patients

Sixty-seven HCV-positive patients (details in Tables 1 and 2) followed by the Liver Center of the University of Trieste from 1st January 2000 to 1st January 2015, have been studied in the Neurology Unit due to the detection of peripheral neuropathic signs. All the patients were treated with IFN-alpha and ribavirin therapy, three times a week; a progressive decrease of their viral load was observed in all of them. Neurological signs of peripheral neuropathic signs appeared for 11 patients 9.7 ± 2.1 months after the cessation of antiviral therapy even with a sustained viral response, and increase in the cryoglobulins serum level. Forty-four patients interrupted antiviral therapy (mean period of treatment of 7.6 9.7 ± 2.1) due to neurological symptoms such as anxiety and depression (18 patients), suicidal thoughts (6 patients), major sleeping disturbances, concentration difficulties and daily living executive complications (8 patients), apathy, chronic fatigue, loss of weight (12 patients). Drop out are in line with some data presented in Literature, i.e. by Manns et al. [32, 33] All the 44 patients showed cryoglobulin neuropathic polyneuropathy 3.4 ± 1.2 months after stopping antiviral therapy. Twelve patients were strained to interrupt the IFN and ribavirin therapy (after mean time of therapy duration of 6.2 ± 3.9 months) due to the appearance of painful peripheral

#### Table 1 
Epidemiological and biological features in 67 patients with HCV and cryoglobulinemia

| Patients (total 67) | Features |
|--------------------|----------|
| Age (years)        | 50.4 ± 2.7 |
| Sex ratio (M/F)    | 31/36 |
| Apparent duration of disease (years) | 4.1 ± 1.3 |
| Albumin level (g/L) | 39.7 ± 8.5 |
| ALT (IU/L)         | 131.4 ± 16.7 |
| Prothrombin time (%) | 84.1 ± 12.2 |
| Rheumatoid factors (n of pts. and %) | 41/67 (61%) |
| Mean Cryoglobulinemia(g/L) | 0.27 ± 0.8 |

| Cryoglobulinemia type | Features |
|-----------------------|----------|
| CGS TYPE II (n of pts. and %) | 42/67 (64%) |
| CGS TYPE III (n of pts. and %) | 25/67 (36%) |
| ANTI HCV Antibodies (n of pts. and %) | 67/67 (100%) |
| ANTI HBV Antibodies (n of pts. and %) | 35/67 (52%) |
| Anti HBC | 30 (86%) |
| HBsAg | 5 (14.2) |
| Anti HBS | 30 (86%) |
| HBcAg | 0 |
| AntiHBe | 0 |

HCV RNA sequences in sera (n of pts. and %) 49/67 (73%)
neuropathy, associated with an elevation of cryoglobulinemia, and therefore excluding the IFN-related neuropathy.

The new antiviral drugs (sofusbuvir, simeprevir, daclatasvir, etc.) were not used, since at the time of the recruitment they were not available. All of the 67 patients reported progressive painful paresthesias, shock pain episodes, boot-glove dysesthesia sensations. All the patients showed signs of cryoglobulinemia (mean 0.27 +/− 0.8 g/L; range 0.05–1.6 g/L). Cryocrit levels were measured as the percentage of packed cryoglobulins after cold centrifugation of the serum, and cryoglobulin composition was determined by immunodiffusion on Ouchterlony plates against specific antisera. Fifty-eight had polyneuropathy and 9 had mononeuropathy multiplex. All subjects had an electroneurographic confirmation of peripheral neuropathy, 57 presented the axonal profile and 10 showed the axonal-demyelinating signs of damage (Table 3). Thirty-six patients referred a relatively acute onset of pain and numbness in feet and legs together with a rash on the dorsal surface of low limbs, in particular, starting from the feet, extending midway up to the legs. Seventeen patients presented with the acute onset of pain, described as “electric shocks” which is followed by numbness in legs. These symptoms started approximately two years prior presentation of overt liver disease, and gradually worsened. Fourteen patients (all women) presented a mainly sensory neuropathy, asymmetrical, with dysesthesia symptoms and were committed due to a presumptive restless leg syndrome, which was not confirmed by the neurologist. All the patients denied any other symptom such as fever, chills, arthralgias or skin alterations, apart from those described above, or other general hepatic-referable symptoms; 24 patients admitted alcohol consumption before the beginning of IFN-alpha and ribavirin therapy.

Reduced complement C4 activity has been found in 39 patients; positive search for antinuclear antibodies has been found in 13 patients, anti-mitochondrial in 19 patients and C-reactive protein has been found in 32 patients.

**Pharmacological treatment**

As shown in Fig. 1, after the electroneurographic confirmation of the clinical diagnosis of cryoglobulinemia related polineuropathy, patient started a cycle of steroids for 14 days, followed by Gabapentin if steroids failed to improve the symptoms. If Gabapentin treatment was not successful or accompanied by side effects, it was substituted with Pregabalin, witch was soon interrupted for severe side effects. After one month of wash-out, all the 67 patients, who still complained for the neurological symptoms began

---

**Table 2** HCV status of the 67 patients

| Features                  | Patients (total 67) (number and %) |
|---------------------------|-----------------------------------|
| Anti HCV antibodies       | 67/67 (100%)                      |
| Chronic Hepatitis         | 67/67 (100%)                      |
| Cirrhosis                 | 6/67 (8.9%)                       |
| Presumed disease duration (years) | 6.1 ± 2.7                     |
| Fibrosis score            | 1.9 ± 0.7                         |
| HAI score [47]            | 6.5 ± 1.2                         |
| HCV genotype (number and %) |                                    |
| 1                         | 43 (64.1%)                        |
| 2                         | 1 (1.5%)                          |
| 3                         | 21 (31.3%)                        |
| 4                         | 2 (3%)                            |

**Table 3** Electrophysiological and clinical features of the examined patients

| Symptoms                          | Patients |
|-----------------------------------|----------|
| Neurology type                    |          |
| Polyneuropathy                    | 58       |
| Mononeuropathy                    | 9        |
| Electrophysiological features     |          |
| Demyelination                     | 10       |
| Axonal                            | 57       |
Oxcarbazepine. A neurological assessment was performed every month for 12 months after the start of Oxcarbazepine treatment.

Statistical analyses
Statistical analyses were performed using SAS® software (version 16.0 SAS® Software Inc., Cary, NC, USA). Within-group changes from baseline were tested using the Wilcoxon Signed Ranks test. Between-group comparisons of changes from baseline were tested using the Marginal Homogeneity Test. Spearman correlation test has been employed for each significant variable. This was done for each efficacy variable. Results are presented as mean changes from baseline with standard deviations, and p-values are provided where appropriate.

Results
As in Fig. 1, after the clinical diagnosis all patients were treated with steroids (up to 100 mg/daily of prednisone); 10 patients partially responded, 40 experienced steroidal side effects, which causes interruption, and 17 did not show any benefit.

One month after the steroid washout, gabapentin. It was prescribed (1887 ± 205 mg/day) followed by a moderate improvement in the painful sensation (average visual analog scale from 8 to 9 to 6–7). After one month of follow-up, due to daytime sleepiness, nausea, dizziness and gait alteration the drug was stopped. The average duration of the treatment was 1.4 ± 1.2 months.

In 23 strongly motivated patients, pregabalin (50 mg, t.i.d) was prescribed; 14 patients showed cholestatic and liver damage, 2 presented overt jaundice and 7 patients a prolongation of the prothrombin time. All side effects subsided after the medication was stopped. No amelioration of pain symptoms was observed.

At the end of this period of treatment (average time of 5.6 months), all the 67 patients reported side effects and persistence of pain. After two weeks of washout of any other pain-relief drug(s), oxcarbazepine was given at a dose of 300 mg/day for a week, increased to 600 mg/day the following week, and then further increased to 900 mg/day. The dosage was increased to 1200 mg/day in 11 patients for 10.2 ± 2.3 days, due to persistence of pain, to be then readjusted to 900 mg/day. Each patients was follow-up monthly for 12 months, and each check-up, the Short form McGill Pain Assessment Questionnaire (SF-MPQ) [34] was administered. The average SF-MPQ was 32.1 ± 5.7 at baseline (average scores 24–36), and decreased to 21.3 ± 2.3 (average scores 17–25, p < 0.001) after one month. The average SF-MPQ at 6-month was 12.5 ± 3.7 (average scores 9–14; p < 0.001 over baseline). At the 6th month of follow-up, the dose of Oxcarbazepine was reduced to 600 mg/day; 33 patients were pain free and maintained the dose for two additional months while 34 increased to 900 mg/day. All the 67 patients, who have been prescribed Oxcarbazepine, completed the 12 months follow-up: 46 patient were asymptomatic and do not take any anti-epileptic drug. All patients referred sleepiness and drowsiness at the beginning of the therapy that rapidly disappeared; no other side effects were observed.

Discussion
Hepatitis C is a serious health concern, affecting millions of people worldwide. The majority of the subject positive for HCV antibody are asymptomatic. More recently, central (CNS) and peripheral nervous system (PNS) have been studied as focal collateral damage regions, tightly involved in HCV.

The treatment of HCV-cryoglobulins-associated PNS is actually based IFN plus ribavirin therapy, eventually associated with steroids [4, 35–37]. Studies have showed that patients with HCV-associated cryoglobulinemia and extra-hepatic manifestations treated with IFN-alpha alone were reported to be responders (resolution of symptoms, disappearance of cryoprecipitates and HCV RNA), with only one tapering off of IFN-alpha after 3 years of treatment with sustained resolution of HCV and cryoglobulinemia [34]. However, long-term studies were not performed and the results of long term follow-up are not available [38–40]. The few data available seems to indicate favorable outcomes in cryoglobulinemia HCV subjects treated with corticosteroids [10, 39, 40]. Since chronic steroid administration also increases the level of HCV RNA, this treatment should be limited. Therefore, intravenous immunoglobulin or plasmapheresis should be considered as a therapeutic option [24]. In addition, in patients with severe cryoglobulinemia-associated vasculitis as those with rapidly progressive renal failure or neurological involvement, the antiviral therapy should be delayed for 2–4 months while they are treated with aggressive scheme with plasmapheresis, high doses of corticosteroids and either cyclophosphamide or rituximab [41]. Rituximab therapy has been used predominantly in HCV-related mixed cryoglobulinemia refractory to or unsuitable for corticosteroids and antiviral (IFN-α) therapy [41]. The role of interferon to exacerbate cryoglobulinemia related neuropathy is still under evaluation, although recent data obtained in 24 patients showed that interferon-free regimen with new drugs as sofosbuvir resulted in an almost complete clinical response of the vasculitis but still undefined effect on pain relief [42].

Painful neuropathy is a dramatic and persistent condition, which affects many patients, and is an invalidating condition. The several options available for pain control are confusing and daunting. The best solution seems to be an escalating regime matching the intensity and nature of the sensory components of the pain state. Moreover, in
chronic conditions, such as HCV-related hepatitis, where many different clinical details should be considered, pain relief therapies should not interfere with the underline disease and the concomitant antiviral treatment. Therefore, pain-treatment should be efficacious, should not interfere with their general and hepatic condition, should not create side effects as, in particular, disequilibrium, gait imbalance, drowsiness and reduced vigilance.

Oxcarbazepine is a safe drug, without significant side effects, and the rarely described hepatotoxicity seems to be related to a hypersensitivity or to a immune –mediated response to some metabolites of the drug, rapidly and totally reversible [43]. Oxcarbazepine should be carefully monitored by specialists, with reported side effects, which can be distinguished in: more common, but rapidly and spontaneously solving side effects (1:100): Blurred vision, disequilibrium, mental depression, emotional incontinence, cough and sore throat sensation. Less common (less than 1:1000): Agitation, awkwardness, mental confusion, persistent disequilibrium associated with orthostatic hypotension, fast or irregular heartbeat, thirst, muscle cramps, headache, skin rash, weakness. Usually they spontaneously disappeared, and they do not need a suspension of therapy.

Oxcarbazepine possess intrinsic pain-relief properties [44], either considering acute or chronic pain [44, 45] and neuropathic pain [46]. The efficacy of previous studies, its safety, the good tolerance and the limited side effects leads to this study, which confirmed the previously reported data [10]. Results are stable, we have not reported serious adverse side effects and pain relief is stable. Our study demonstrated that treatment of HCV-cryoglobulins related neuropathy with oxcarbazapine is effective in the large majority of patients at a dosage which is rather well tolerated and is not associated with any relevant side effect. The particular condition of these patients (particularly vulnerable to hepatotoxicity), the conspicuous potential interactions with concomitant drugs taken by the patients (antiviral, etc), the rapid beneficial effect (demonstrated by the decrease of the average SF-MPQ), and the absence of consistent side effects (demonstrated by a good pattern of labs values) favour to the use of oxcarbazepine in the management of neuropathic pain.

Conclusions

In this work, patients not responsive to steroids, gabapentin at high dosage and to pregabalin, benefit from oxcarbazepine. The limited side effects, associated to the favourable and rapid response, the reduced interaction with concomitant drugs support the use of oxcarbazepine as an effective and safe treatment of the of HCV-cryoglobulins related neuropathy.

Abbreviations

CNS: Central nervous system; GGT: Gamma-glutamyltranspeptidase; HAV: Hepatitis A virus; HBV: Hepatitis B virus; HCV: Hepatitis C virus; IFN: Interferon; IFN-alpha: Interferon-alpha; MHD: 10-hydroxcarbazepine; PNS: Peripheral nervous system; SF-MPQ: Short form McGill Pain Assessment Questionnaire; VAS: Visual analogue scale

Acknowledgments

Not applicable.

Funding

MDB was partially supported by the fellowship U12GPFIRB11. This study was supported in part by ad in house grant of Fondazione Italiana Fegato (Italian Liver Foundation).

Availability of data and materials

All data generated or analyzed during this study are not publicly available due to confidentiality, but are available from Dr. Rita Moretti on reasonable request.

Authors’ contributions

RM designed the experimental plan, evaluated the patients, collected and analyzed data. RM, PC, MDB, CT, SG critical revised the work and prepared the manuscript. All authors have read and approved the final version of the submitted manuscript.

Ethics approval and consent to participate

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Guidelines of the Cattinara Hospital Etic Committee. The patients gave their written informed consent to participate to the study.

Consent for publication

The patients gave their written informed consent to publish the study.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Neurology Clinic, Department of Medical, Surgical, and Health Sciences, University of Trieste, 34100 Trieste, Italy. 2Italian Liver Foundation, Centro Studi Fegato, AREA Science Park, Bldg. Q, Ss 14, km 163.5, 34149 Trieste, Italy.

Received: 12 September 2017 Accepted: 21 January 2018
Published online: 25 January 2018

References

1. Ramos-Casals M, Stone JH, Ciccia C, Bosch X. The cryoglobulinaemias. Lancet Lond Engl. 2012;379:348–60.
2. Brouet JC, Clauvel JP, Donan F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57:775–88.
3. Lidove O, Cacoub P, Maizonbe T, Servan J, Thibault V, Pette JC, et al. Hepatitis C virus infection with peripheral neuropathy is not always associated with cryoglobulinemia. Ann Rheum Dis. 2001;60:290–2.
4. Trejo O, Ramos-Casals M, García-Carrasco M, Yagüe J, Jiménez S, de la Red G, et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore). 2001;80:252–62.
5. Nemni R, Savuto L, Quattrini A, Santuccio G, Camerlingo M, Canal N. Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinemia. J Neurol Neurosurg Psychiatry. 2003;74:1267–71.
6. Trendelenburg M, Schifferli JA. Cryoglobulins are not essential. Ann Rheum Dis. 1998;57:3–5.
7. Gorevic PD, Kasab HJ, Levo Y, Kohn R, Meltzer M, Prose P, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med. 1980;69:287–308.

8. Bonetti B, Monaco S, Giannini C, Ferrari S, Zanussi G, Rizzuto N, Human peripheral nerve macrophages in normal and pathological conditions. J Neurosci. 1993;13(2):158–68.

9. Sansonno D, Coniacchieto V, Iacobelli AR, Di Stefano R, Lospalluti M, Dammacco F. Localization of hepatitis C virus antigens in liver and skin tissues of chronic hepatitis C virus-infected patients with mixed cryoglobulinemia. Hepatol Baltim Md. 1995;21:305–12.

10. Moretti R, Torre P, Antonello RM, Cattaruzza T, Pizzolato G. Peripheral neuropathy in hepatitis C virus-related mixed cryoglobulinemia: existing treatments and a positive symptomatic response to oxcarbazepine. Funct Neurol. 2006;21:137–40.

11. Tembl J, Ferrer JM, Sevilla MT, Lago A, Mayordomo F, Vilchez JJ. Neurologic complications associated with hepatitis C virus infection. Neurology. 1999;53:861–4.

12. Beckmann KG, Kayser C, Heus D, Manger B, Blum HE, Neudorfer B. Neurological manifestations of chronic hepatitis C. J Neurol. 1999;246:486–91.

13. Monaco S, Ferrari S, Gapofato A, Zanussi G, Maricotti S. HCV-related nervous system disorders. Clin Dev Immunol. 2012;2012:236148.

14. Carvalho-Filho RJ, Narciso-Schivan JL, Tolentino LHL, Schiavan LL, Ferraz MLG, AEB S. Central nervous system vasculitis and polyneuritis as first manifestations of hepatitis C. World J Gastroenterol. 2012;18:188–91.

15. Zaltron S, Puoti M, Liberti P, Antonini L, Quinzanini M, Manni M, et al. High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinemia. Ital J Gastroenterol Hepatol. 1998;30:91–5.

16. De Martino L, Sampalo S, Tucci C, et al. Viral RNA in nerve tissue of patients with hepatitis C infection and peripheral neuropathy. Muscle Nerve. 2003;27(1):102–4.

17. Younis KS, Talaat FM, Deif AH, Diller B, Reheim SM, El Salmawy DH. Immunohistochemical detection of HCV in nerves and muscles of patients with HCV-associated peripheral neuropathy and Myositis. Int J Health Sci (Qassim). 2007;1(2):195–202.

18. Mhea S, Levey JM, Bonkovsky HL. Extravagant manifestations of infection with hepatitis C virus. Clin Liver Dis. 2001;5:979–1008.

19. Lidove O, Maisonneve T, Servan J, Thibault V, Lievre JM, Piette J-C. Peripheral neuropathy and hepatitis C virus infection: more than cryoglobulinemia. Rev Med Int. 2001;22:939–47.

20. Bonetti B, Scardoni M, Monaco S, Rizzuto N, Scarpa A, Caccavelli C. Hepatitis C virus peripheral infection of nerves in type II cryoglobulinemia. Vieches Arch Int J Pathol. 1999;43:533–5.

21. Aparisi E, Leger JM, Musset L, Gugenheim M, Caccavelli P, Lyon-Caen O, et al. Peripheral neuropathy associated with essential mixed cryoglobulinemia: a role for hepatitis C virus infection? J Neurol Neurosurg Psychiatry. 1996;60:661–6.

22. Gennimati F, Meli M, Grinque C, Marinai M. Cryoglobulinemia is a frequent cause of peripheral nerve macrophages in unrefractory patients. J Peripheral Nerv Syst. 2002;5:79–64.

23. Chin RL, Sander HW, Brannaga TH, De Sousa E, Latov N. Demyelinating neuropathy in patients with hepatitis C virus infection. J Clin Neuromuscular Disease. 2010;1(1):209–12.

24. Vishal S, Yoinhika K, Biplob Singh N, Ningshen R, Bhimo Singh T. Demyelinating neuropathy: a rare presentation of hepatitis C infection without mixed cryoglobulinemia. JACOM. 2016;1(1):50–3.

25. Conca P, Caffaro G, de Renzo A, Coppola A, Cimino E, Tarantino G. Successful and safe long-term standard anti-viral therapy in a patient with explosive immune response in course of HCV-related liver cirrhosis. Int J Mol Sci. 2015;16:4075–85. https://doi.org/10.3390/ijms160614075.

26. Carvalho A, Santos Garcia JB, de Sousa Furtado I. Peripheral neuropathy associated to cryoglobulinemia in patients with hepatitis C. Case report and literature review. Rev. Do Sao Paulo. 2013;14(1):71–5.

27. Levine JW, Cota F, Fesler J, Calabrese LH. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis virus. J Rheumatol. 2005;32(6):1164–7.

28. La Civita L, Zignego AL, Lombardi F, Monti M, Longombardo G, Paseo G, et al. Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. J Rheumatol. 1996;23:1641–3.

29. Boonyapisit K, Katirji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve. 2002;25:909–13.

30. Ballaré M, Bobbio F, Foggi S, Bordin G, Bertocchini MC, Catania E, et al. A pilot study on the effectiveness of cyclosporine in type II mixed cryoglobulinemia. Clin Exp Rheumatol. 1995;13(Suppl 13):5201–3.

31. Muri H, Inaba S, Kira J, Yamamoto A, Ohno M, Goto I. Hepatitis C virus associated cryoglobulinemic neuropathy successfully treated with plasma exchange. Antif Organs. 1995;19:334–8.

32. Manns MP, Wiedemann H, Comberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55(9):1350–9.

33. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37:445–51.

34. Melzack R. The short form McGill pain questionnaire. Pain. 1987;30:191–7.

35. Naarendop M, Kallenchickluk U, Nieuw GJ, Gorevic PD. Long-term efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol. 2001;28:2466–73.

36. Cacoub P, Lidove O, Maisonneve T, Duhaud P, Thibault V, Ghillari P, et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 2002;46:3317–26.

37. Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette J-C. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 2005;52:911–5.

38. Toyooka K, Fujimura H. Iatrogenic neuropathies. Curr Opin Neurol. 2009;22:475–9.

39. Cacoub P, Sbaa A, Hauspater F, Pipa T, Gallet A, Piette J-C. Central nervous system involvement in hepatitis C virus infection. Gastroenterol Clin Biol. 1998;22:631–3.

40. Dawson TM, Starkebaum G. Isolated central nervous system vasculitis associated with hepatitis C infection. J Rheumatol. 1999;26:2273–6.

41. Kamar N, Rostaing L, Alric L. Treatment of hepatitis C virus-related glomerulonephritis. Kidney Int. 2006;69:436–9.

42. Saadoun D, Thibault V, Si Ahmed SN, Alric L, Mallet M, Guillaud C, Izedine H, Plaisier A, Fontaine H, Costopoulos M, Le Gaff-Tavernier M, Hexode C, Pol S, Musset L, Pouyand T, Caccavelli P, Sotoosubue plus ribavirin for hepatitis C virus-associated cryoglobulinemia vasculitis: VASCULADIC study. Ann Rheum Dis. 2016;75(10):1777–82. https://doi.org/10.1136/annrheumdis-2015-208339.

43. Shannon HE, Eberle EL, Peters SC. Comparison of the effects of anticonvulsant drugs with diverse mechanisms of action in the formalin test in rats. Neuropharmacology. 2005;48:1012–20.

44. Criscuolo S, Auletta C, Lippi S, Brogi F, Brogi A. Oxcarbazepine (Trileptal) monotherapy dramatically improves quality of life in two patients with postherpetic neuralgia refractory to carbamazepine and gabapentin. J Pain Symptom Manag. 2004;28:535–6.

45. Criscuolo S, Auletta C, Lippi S, Brogi F, Brogi A. Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin. Acta Neurol Scand. 2005;111:229–32.

46. Luef G, Poeewe W. Oxcarbazepine in glossopharyngeal neuralgia: clinical response and effect on serum lipids. Neurology. 2004;63:2447–8.

47. Knodell RG, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1(3):431–5.